Renalytix Plc
RTNXF
Other OTC0.08
USD
- -
- -
CIK
0001811115
ISIN
GB00BYWL4Y04
Return %
Stock
S&P500
1Y
-76.47
26.53
3Y
-98.88
76.60
5Y
-97.95
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James R. McCullough
- Full Time Employees
- 102
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 1460 Broadway New York City NY United States of America 10036
- IPO Date
- May 15, 2019
- CIK
- 0001811115
- Website
- renalytix.com
- Similar Companies
- Business
- Renalytix Plc (LSE: RENX; OTCQB: RNLXY) develops artificial intelligence-enabled in vitro diagnostic solutions for kidney disease risk assessment; the company offers KidneyIntelX.dkd, an FDA-approved and Medicare-reimbursed prognostic blood test that combines blood-based biomarkers, genetics, and electronic health record data to stratify patients with type 2 diabetes and early-stage chronic kidney disease (stages 1-3b) into low, moderate, or high risk categories for rapid kidney function decline over five years; it also provides pharmaceutical services leveraging its biomarker portfolio and KidneyIntelX technology for clinical research and drug development support. Incorporated in 2018 and headquartered in New York with a registered office in London, United Kingdom, Renalytix primarily operates in the United States, targeting primary care physicians, nephrologists, and health systems in key markets including New York, Texas, Florida, and Arizona; the company serves approximately 14 million U.S. patients with diabetic kidney disease through electronic medical record integrations that automate patient identification and physician alerts. Recent developments include full Medicare coverage at $950 per test achieved in May 2024, a commercial launch with Advantage Care Physicians serving over 500,000 patients in September 2024, a September 2025 collaboration with Tempus AI to expand national access via precision medicine platforms, and a partnership with MVP Health Care in August 2025 covering 770,000 members in New York and Vermont; the company completed an £11.8 million institutional fundraise in November 2024 and a £6.7 million oversubscribed raise in September 2025, restructured convertible debt to reduce cash obligations by over 80% and extend maturities to 2029, transitioned U.S. trading to OTCQB from Nasdaq in October 2024, appointed Julian Baines as Executive Chairman in 2024 (transitioning to Non-Executive Chairman in January 2026), and reported 30% revenue growth to $3.0 million for fiscal year 2025 with testing volumes up 37%.